Baudax Bio (BXRX) Short Interest Ratio & Short Volume

Short interest is the volume of Baudax Bio shares that have been sold short but have not yet been closed out or covered. As of November 15th, investors have sold 473,100 shares of BXRX short. 1.11% of Baudax Bio's shares are currently sold short. Learn More on Baudax Bio's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.11% of Baudax Bio's floating shares are currently sold short.

Baudax Bio saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 473,100 shares, a decrease of 0.3% from the previous total of 474,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Baudax Bio currently has issued a total of 52,460,000 shares. Some of Baudax Bio's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Baudax Bio currently has a public float of 42,620,000 shares.

1.11% of Baudax Bio's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Baudax Bio: Sunshine Biopharma, Inc. (7.32%), Biodexa Pharmaceuticals Plc (14.70%), Comera Life Sciences Holdings, Inc. (2.38%), SciSparc Ltd. (21.38%), GRI Bio, Inc. (0.61%), Panbela Therapeutics, Inc. (2.36%), Evelo Biosciences, Inc. (2.11%), NeuBase Therapeutics, Inc. (0.81%), 180 Life Sciences Corp. (3.30%), InMed Pharmaceuticals Inc. (1.89%),

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($7.24 billion), T-Mobile US, Inc. ($4.02 billion), Charter Communications, Inc. ($3.72 billion), Occidental Petroleum Co. ($2.80 billion), Lululemon Athletica Inc. ($2.48 billion), Coinbase Global, Inc. ($2.38 billion), Tractor Supply ($2.35 billion), Rivian Automotive, Inc. ($1.79 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Moderna, Inc. ($1.71 billion). View all of the most shorted stocks.

Short selling BXRX is an investing strategy that aims to generate trading profit from Baudax Bio as its price is falling. BXRX shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Baudax Bio occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BXRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BXRX, twice per month. The most recent reporting period available is November, 15 2023.